Literature DB >> 4022091

Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses.

N A Halsey, R Boulos, F Mode, J Andre, L Bowman, R G Yaeger, S Toureau, J Rohde, C Boulos.   

Abstract

To study the factors affecting the serologic response to measles vaccination, we evaluated 595 Haitian infants from 6 through 12 months of age, and their mothers, at the beginning of an immunization program. Thirty-four per cent of the infants had preexisting serologic evidence of measles infections by 11 months of age. Among infants more than nine months of age, those who had had measles had a significantly lower nutritional status than those who had not (P less than 0.01). After vaccination, seroconversion rates increased from 45 per cent at 6 months to 100 per cent at 12 months. The lowest rate of vaccine failure compatible with acceptably low rates of natural infections could be achieved by vaccination after eight months of age. Infants born to mothers with low levels of antibody to measles (hemagglutination-inhibition antibody titers less than 1:40) were significantly more likely to have had natural measles (P less than 0.01) or to have seroconversion after vaccination (P less than 0.001) at 6 to 10 months of age than were infants born to mothers with higher of age than were infants born to mothers with higher titers. Malnutrition and acute infections did not affect seroconversion rates. These data support the World Health Organization recommendation to administer measles vaccine in under-developed countries as soon after nine months of age as possible, regardless of nutritional status or the presence of minor illnesses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4022091     DOI: 10.1056/NEJM198508293130904

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  28 in total

1.  Loss of maternally acquired measles antibodies in well-nourished infants and response to measles vaccination, Peru.

Authors:  A Vaisberg; J O Alvarez; H Hernandez; D Guillen; P Chu; A Colarossi
Journal:  Am J Public Health       Date:  1990-06       Impact factor: 9.308

2.  Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. Should we be concerned?

Authors:  B Watada; K Kennedy; D Chan; B Church; M Patriquin; F Shariff; M F Evans
Journal:  Can Fam Physician       Date:  1998-01       Impact factor: 3.275

Review 3.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

4.  Modelling the first dose of measles vaccination: the role of maternal immunity, demographic factors, and delivery systems.

Authors:  C J E Metcalf; P Klepac; M Ferrari; R F Grais; A Djibo; B T Grenfell
Journal:  Epidemiol Infect       Date:  2010-06-07       Impact factor: 2.451

5.  Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses.

Authors:  C Nicoara; K Zäch; D Trachsel; D Germann; L Matter
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

6.  USEFULNESS OF EVALUATION OF ANTIMEASLES ANTIBODIES IN PRETERM BABIES.

Authors:  G S Chopra; P K Sarkar; A Dhulia
Journal:  Med J Armed Forces India       Date:  2011-07-21

7.  Ideal age for measles vaccination with persisting maternal antibody, human immunodeficiency virus infection and protein-calorie malnutrition.

Authors:  S C Arya
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

Review 8.  The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age.

Authors:  N Halsey; A Galazka
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

9.  Bayesian inference for skew-normal mixture models with left-censoring.

Authors:  Getachew A Dagne
Journal:  J Biopharm Stat       Date:  2013       Impact factor: 1.051

10.  Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus.

Authors:  Chien-Hsiung Pan; Gretchen S Jimenez; Nitya Nair; Qun Wei; Robert J Adams; Fernando P Polack; Alain Rolland; Adrián Vilalta; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.